Unknown

Dataset Information

0

Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

ABSTRACT: Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson's disease.

SUBMITTER: Panarese JD 

PROVIDER: S-EPMC6421540 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu<sub>4</sub> PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive <i>in vitro</i> and <i>in vivo</i> pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate  ...[more]

Similar Datasets

Unknown Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5.
| S-EPMC4789665 | biostudies-literature
Unknown Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.
| S-EPMC4492464 | biostudies-literature
Unknown Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).
| S-EPMC5031509 | biostudies-literature
Unknown Discovery of VU0467485/AZ13713945: An M<sub>4</sub> PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.
| S-EPMC5304297 | biostudies-literature
Unknown MK-7622: A First-in-Class M<sub>1</sub> Positive Allosteric Modulator Development Candidate.
| S-EPMC6047034 | biostudies-literature
Transcriptomics REPROGRAMMING CBX8-PRC1 FUNCTION WITH A POSITIVE ALLOSTERIC MODULATOR
2022-01-03 | GSE182592 | GEO
Unknown Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.
| S-EPMC8689142 | biostudies-literature
Unknown Discovery of an intrasubunit nicotinic acetylcholine receptor-binding site for the positive allosteric modulator Br-PBTC.
| S-EPMC6690704 | biostudies-literature
Genomics Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7
2019-08-13 | GSE135762 | GEO
Unknown Discovery of a Negative Allosteric Modulator of GABAB Receptors.
| S-EPMC4094264 | biostudies-literature